Market capitalization | €18.23b |
Enterprise Value | €20.61b |
P/E (TTM) P/E ratio | 106.24 |
EV/FCF (TTM) EV/FCF | 88.70 |
EV/Sales (TTM) EV/Sales | 7.54 |
P/S ratio (TTM) P/S ratio | 6.66 |
P/B ratio (TTM) P/B ratio | 4.67 |
Dividend yield | 0.37% |
Last dividend (FY23) | €0.69 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
15 Analysts have issued a Sartorius Stedim Biotech forecast:
15 Analysts have issued a Sartorius Stedim Biotech forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2,736 2,736 |
8%
8%
|
|
Gross Profit | 1,143 1,143 |
21%
21%
|
|
EBITDA | 638 638 |
33%
33%
|
EBIT (Operating Income) EBIT | 354 354 |
51%
51%
|
Net Profit | 169 169 |
63%
63%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions and focus on single-use technologies are supporting biopharma companies around the world to develop and produce drugs safely, timely and economically. The company's product portfolio include cell analysis, cell culture media and buffers, bioreactors fermenters, lab filtration & purification, process filtration & purification, fluid management, process control & data analytics, industrial microbiology, water purification, weighing, pipetting & dispensing OEM, centrifuges and lab catalogs. Sartorius Stedim Biotech was founded in 1978 and is headquartered in Aubagne, France.
Head office | France |
CEO | René Fáber |
Employees | 10,662 |
Founded | 1978 |
Website | www.sartorius.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.